TABLE 2.
Univariate analysis of survival rates for entire cohort by Cox regression
| Variables | OS | PFS | LPFS | DMFS | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Gender (male as ref.) | 0.22 (0.06‐0.78) | .019 | 0.40 (0.19‐0.83) | .015 | 0.21 (0.06‐0.75) | .016 | 0.66 (0.21‐2.01) | .46 |
| Age (≤49 y vs >49 y) | 2.06 (0.78‐5.46) | .15 | 1.29 (0.66‐2.53) | .46 | 1.76 (0.66‐4.74) | .26 | 0.81 (0.26‐2.50) | .72 |
| Histology (others as ref.) | ||||||||
| Sarcoma | 5.49 (1.87‐16.08) | .02 | 2.51 (1.16‐5.45) | .20 | 1.2 (0.39‐3.74) | .75 | 4.42 (1.28‐15.3) | .019 |
| Melanoma | 4.4 (1.09‐17.8) | .038 | 3.5 (1.37‐9.0) | .009 | 0 | .98 | 6.14 (1.42‐26.5) | .015 |
| T categories (T1/2 vs T3/4) | 0.37 (0.14‐0.99) | .047 | 0.44 (0.21‐0.95) | .036 | 0.59 (0.19‐1.84) | .36 | 0.38 (0.12‐1.22) | .10 |
| N categories (N0 vs N1‐3) | 2.72 (0.87‐8.46) | .09 | 2.86 (1.23‐6.66) | .015 | 1.17 (0.27‐5.18) | .83 | 3.07 (0.84‐11.24) | .09 |
| GTV (continuous variable) | 1.01 (1.0‐1.02) | .14 | 1.00 (1.0‐1.01) | .21 | 1.0 (0.99‐1.01) | .72 | 1.01 (1.0‐1.02) | .028 |
| Tumor status (primary vs recurrence) | 1.7 (0.65‐4.46) | .27 | 1.29 (0.65‐2.59) | .47 | 1.46 (0.54‐3.92) | .46 | 0.93 (0.29‐3.04) | .91 |
| Radiotherapy (RT‐naive vs re‐irradiation) | 1.71 (0.61‐4.78) | .31 | 1.18 (0.56‐2.47) | .66 | 2.14 (0.80‐5.75) | .13 | 0.23 (0.03‐1.77) | .16 |
| Surgery (surgery vs without surgery + biopsy) | 0.92 (0.34‐2.49) | .92 | 0.98 (0.48‐1.99) | .96 | 1.07 (0.39‐2.95) | .90 | 1.09 (0.36‐3.35) | .88 |
| BED (continuous variable) | 1.03 (0.93‐1.13) | .64 | 1.01 (0.94‐1.08) | .79 | 0.97 (0.89‐1.05) | .44 | 1.07 (0.95‐1.21) | .26 |
Abbreviations: BED, biological equivalent dose; DMFS, distant metastasis‐free survival; HR, Hazard ratio; LPFS, local progression‐free survival; OS, overall survival; PFS, progression‐free survival.
Statistically significant differences indicated in bold type.